These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26384346)

  • 1. MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma.
    Fisel P; Stühler V; Bedke J; Winter S; Rausch S; Hennenlotter J; Nies AT; Stenzl A; Scharpf M; Fend F; Kruck S; Schwab M; Schaeffeler E
    Oncotarget; 2015 Oct; 6(31):30615-27. PubMed ID: 26384346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses.
    Kim Y; Choi JW; Lee JH; Kim YS
    Hum Pathol; 2015 Jan; 46(1):104-12. PubMed ID: 25456395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
    Cao YW; Liu Y; Dong Z; Guo L; Kang EH; Wang YH; Zhang W; Niu HT
    Urol Oncol; 2018 Jun; 36(6):311.e15-311.e25. PubMed ID: 29657088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of lactate/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder.
    Choi JW; Kim Y; Lee JH; Kim YS
    Urology; 2014 Jul; 84(1):245.e9-15. PubMed ID: 24857275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231.
    Gallagher SM; Castorino JJ; Wang D; Philp NJ
    Cancer Res; 2007 May; 67(9):4182-9. PubMed ID: 17483329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer.
    Pinheiro C; Longatto-Filho A; Simões K; Jacob CE; Bresciani CJ; Zilberstein B; Cecconello I; Alves VA; Schmitt F; Baltazar F
    Eur J Cancer; 2009 Sep; 45(13):2418-24. PubMed ID: 19628385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target.
    Gerlinger M; Santos CR; Spencer-Dene B; Martinez P; Endesfelder D; Burrell RA; Vetter M; Jiang M; Saunders RE; Kelly G; Dykema K; Rioux-Leclercq N; Stamp G; Patard JJ; Larkin J; Howell M; Swanton C
    J Pathol; 2012 Jun; 227(2):146-56. PubMed ID: 22362593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models.
    Schneiderhan W; Scheler M; Holzmann KH; Marx M; Gschwend JE; Bucholz M; Gress TM; Seufferlein T; Adler G; Oswald F
    Gut; 2009 Oct; 58(10):1391-8. PubMed ID: 19505879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma.
    Pinheiro C; Albergaria A; Paredes J; Sousa B; Dufloth R; Vieira D; Schmitt F; Baltazar F
    Histopathology; 2010 Jun; 56(7):860-7. PubMed ID: 20636790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of immunohistochemical staining for myoferlin in clear cell renal cell carcinoma and its association with epidermal growth factor receptor expression.
    Jung M; Lee C; Park JH; Moon KC
    Urol Oncol; 2019 Nov; 37(11):812.e9-812.e16. PubMed ID: 31421995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Four-Gene Promoter Methylation Marker Panel Consisting of
    van Vlodrop IJH; Joosten SC; De Meyer T; Smits KM; Van Neste L; Melotte V; Baldewijns MMLL; Schouten LJ; van den Brandt PA; Jeschke J; Yi JM; Schuebel KE; Ahuja N; Herman JG; Aarts MJ; Bosman FT; Van Criekinge W; van Engeland M
    Clin Cancer Res; 2017 Apr; 23(8):2006-2018. PubMed ID: 27756787
    [No Abstract]   [Full Text] [Related]  

  • 13. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration.
    Gao HJ; Zhao MC; Zhang YJ; Zhou DS; Xu L; Li GB; Chen MS; Liu J
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1151-62. PubMed ID: 25446815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).
    Evelönn EA; Degerman S; Köhn L; Landfors M; Ljungberg B; Roos G
    Tumour Biol; 2016 Aug; 37(8):10219-28. PubMed ID: 26831665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer.
    Pértega-Gomes N; Vizcaíno JR; Miranda-Gonçalves V; Pinheiro C; Silva J; Pereira H; Monteiro P; Henrique RM; Reis RM; Lopes C; Baltazar F
    BMC Cancer; 2011 Jul; 11():312. PubMed ID: 21787388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression.
    Hao J; Chen H; Madigan MC; Cozzi PJ; Beretov J; Xiao W; Delprado WJ; Russell PJ; Li Y
    Br J Cancer; 2010 Sep; 103(7):1008-18. PubMed ID: 20736947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.
    Todenhöfer T; Seiler R; Stewart C; Moskalev I; Gao J; Ladhar S; Kamjabi A; Al Nakouzi N; Hayashi T; Choi S; Wang Y; Frees S; Daugaard M; Oo HZ; Fisel P; Schwab M; Schaeffeler E; Douglas J; Hennenlotter J; Bedke J; Gibb EA; Fazli L; Stenzl A; Black PC
    Mol Cancer Ther; 2018 Dec; 17(12):2746-2755. PubMed ID: 30262589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of monocarboxylate transporter 4 in patients with esophageal squamous cell carcinoma.
    Cheng B; Chen X; Li Y; Huang X; Yu J
    Oncol Rep; 2018 Nov; 40(5):2906-2915. PubMed ID: 30226548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
    Doyen J; Trastour C; Ettore F; Peyrottes I; Toussant N; Gal J; Ilc K; Roux D; Parks SK; Ferrero JM; Pouysségur J
    Biochem Biophys Res Commun; 2014 Aug; 451(1):54-61. PubMed ID: 25058459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of statins on human monocarboxylate transporter 4.
    Kobayashi M; Otsuka Y; Itagaki S; Hirano T; Iseki K
    Int J Pharm; 2006 Jul; 317(1):19-25. PubMed ID: 16621368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.